Unaudited Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:
Net income	$ 12,018	$ 7,765
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	4,219	3,033
Amortization of deferred financing costs	106	12
Accretion of debt discount	0	55
Gain on sale of assets	(558)	(1,132)
Stock compensation expense	2,334	2,241
Deferred income tax (benefit) provision	(290)	301
Excess tax benefit related to share-based awards	(1,300)	(602)
Changes in current assets and liabilities:
Restricted cash	0	150
Accounts receivable, net	(525)	(3,908)
Inventories	(9,863)	341
Other current assets	885	1,814
Accounts payable	6,700	(2,369)
Accrued liabilities	(2,531)	161
Income taxes payable	4,322	161
Interest payable	(12)	(14)
Net cash provided by operating activities	15,505	8,009
Cash flows from investing activities:
Capital expenditures	(4,115)	(4,383)
Proceeds from sale of assets	832	1,388
Payments for acquisition, net of cash acquired	(5,286)	0
Purchase of patents and other intangible assets	(135)	0
Net cash used in investing activities	(8,704)	(2,995)
Cash flows from financing activities:
Repayments of indebtedness	(4,786)	(6,103)
Borrowings on revolving credit facility	96,750	10,000
Repayments on revolving credit facility	(99,097)	(9,244)
Debt issuance costs	(59)	0
Issuance costs of preferred stock and detachable warrants	0	(200)
Excess tax benefit related to share-based awards	1,300	602
Acquisition of treasury stock related to share-based awards	(4,045)	(2,658)
Proceeds from sale of common stock	231	150
Proceeds from exercise of stock options	443	7
Proceeds from exercise of stock warrants	1,545	0
Net cash used in financing activities	(7,718)	(7,446)
Effect of changes in exchange rates on cash and cash equivalents	(149)	(20)
Net decrease in cash and cash equivalents	(1,066)	(2,452)
Cash and cash equivalents at the beginning of period	2,730	2,700
Cash and cash equivalents at the end of period	$ 1,664	$ 248